Browsing Molecular Pathology by author "Sottoriva, Andrea"
Now showing items 1-20 of 32
-
Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer.
Nawaz, S; Trahearn, NA; Heindl, A; Banerjee, S; Maley, CC; et al. (ELSEVIER, 2019-10-21)BACKGROUND: Despite treatment advances, there remains a significant risk of recurrence in ovarian cancer, at which stage it is usually incurable. Consequently, there is a clear need for improved patient stratification. ... -
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; et al. (2017-06)Background Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but ... -
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; et al. (OXFORD UNIV PRESS, 2017-02-23)BACKGROUND: Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but ... -
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.
Stankunaite, R; George, SL; Gallagher, L; Jamal, S; Shaikh, R; et al. (ELSEVIER SCI LTD, 2021-12-18)OBJECTIVE: Clinical diagnostic sequencing of circulating tumour DNA (ctDNA) is well advanced for adult patients, but application to paediatric cancer patients lags behind. METHODS: To address this, we have developed a ... -
Classifying the evolutionary and ecological features of neoplasms.
Maley, CC; Aktipis, A; Graham, TA; Sottoriva, A; Boddy, AM; et al. (NATURE PUBLISHING GROUP, 2017-10-01)Neoplasms change over time through a process of cell-level evolution, driven by genetic and epigenetic alterations. However, the ecology of the microenvironment of a neoplastic cell determines which changes provide adaptive ... -
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.
Lupo, B; Sassi, F; Pinnelli, M; Galimi, F; Zanella, ER; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2020-08-05)Blockade of epidermal growth factor receptor (EGFR) causes tumor regression in some patients with metastatic colorectal cancer (mCRC). However, residual disease reservoirs typically remain even after maximal response to ... -
Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.
Piccirillo, SG; Spiteri, I; Sottoriva, A; Touloumis, A; Ber, S; et al. (AMER ASSOC CANCER RESEARCH, 2015-01-01)Glioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the ... -
Detecting repeated cancer evolution from multi-region tumor sequencing data.
Caravagna, G; Giarratano, Y; Ramazzotti, D; Tomlinson, I; Graham, TA; et al. (NATURE PUBLISHING GROUP, 2018-08-31)Recurrent successions of genomic changes, both within and between patients, reflect repeated evolutionary processes that are valuable for the anticipation of cancer progression. Multi-region sequencing allows the temporal ... -
Detecting truly clonal alterations from multi-region profiling of tumours.
Werner, B; Traulsen, A; Sottoriva, A; Dingli, D (NATURE PORTFOLIO, 2017-03-27)Modern cancer therapies aim at targeting tumour-specific alterations, such as mutations or neo-antigens, and maximal treatment efficacy requires that targeted alterations are present in all tumour cells. Currently, treatment ... -
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
Smyth, EC; Vlachogiannis, G; Hedayat, S; Harbery, A; Hulkki-Wilson, S; et al. (BMJ PUBLISHING GROUP, 2020-11-16)OBJECTIVE: Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome ... -
Evolutionary dynamics of residual disease in human glioblastoma.
Spiteri, I; Caravagna, G; Cresswell, GD; Vatsiou, A; Nichol, D; et al. (OXFORD UNIV PRESS, 2019-03-01)BACKGROUND: Glioblastoma is the most common and aggressive adult brain malignancy against which conventional surgery and chemoradiation provide limited benefit. Even when a good treatment response is obtained, recurrence ... -
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.
Acar, A; Nichol, D; Fernandez-Mateos, J; Cresswell, GD; Barozzi, I; et al. (NATURE PORTFOLIO, 2020-04-21)Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another ... -
Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors.
Zapata, L; Caravagna, G; Williams, MJ; Lakatos, E; AbdulJabbar, K; et al. (NATURE PORTFOLIO, 2023-03-01)In cancer, evolutionary forces select for clones that evade the immune system. Here we analyzed >10,000 primary tumors and 356 immune-checkpoint-treated metastases using immune dN/dS, the ratio of nonsynonymous to synonymous ... -
Immunosuppressive niche engineering at the onset of human colorectal cancer.
Gatenbee, CD; Baker, A-M; Schenck, RO; Strobl, M; West, J; et al. (NATURE PORTFOLIO, 2022-04-04)The evolutionary dynamics of tumor initiation remain undetermined, and the interplay between neoplastic cells and the immune system is hypothesized to be critical in transformation. Colorectal cancer (CRC) presents a unique ... -
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.
Sottoriva, A; Spiteri, I; Piccirillo, SGM; Touloumis, A; Collins, VP; et al. (NATL ACAD SCIENCES, 2013-03-05)Glioblastoma (GB) is the most common and aggressive primary brain malignancy, with poor prognosis and a lack of effective therapeutic options. Accumulating evidence suggests that intratumor heterogeneity likely is the key ... -
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.
Khan, KH; Cunningham, D; Werner, B; Vlachogiannis, G; Spiteri, I; et al. (AMER ASSOC CANCER RESEARCH, 2018-08-30)Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection of patient progression. However, how to exploit the predictive power of cfDNA as a liquid biopsy in the clinic remains unclear. ... -
Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking.
Cresswell, GD; Nichol, D; Spiteri, I; Tari, H; Zapata, L; et al. (NATURE PORTFOLIO, 2020-03-27)Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high resolution, overcoming many limitations of tissue biopsies. However, exploiting ctDNA to determine how a patient's cancer is evolving ... -
Measuring single cell divisions in human tissues from multi-region sequencing data.
Werner, B; Case, J; Williams, MJ; Chkhaidze, K; Temko, D; et al. (NATURE PUBLISHING GROUP, 2020-02-25)Both normal tissue development and cancer growth are driven by a branching process of cell division and mutation accumulation that leads to intra-tissue genetic heterogeneity. However, quantifying somatic evolution in ... -
Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity.
Heindl, A; Khan, AM; Rodrigues, DN; Eason, K; Sadanandam, A; et al. (NATURE RESEARCH, 2018-09-25)How tumor microenvironmental forces shape plasticity of cancer cell morphology is poorly understood. Here, we conduct automated histology image and spatial statistical analyses in 514 high grade serous ovarian samples to ... -
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
Vlachogiannis, G; Hedayat, S; Vatsiou, A; Jamin, Y; Fernández-Mateos, J; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-02-23)Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from ...